In a study by Liu et al., which included 46 unresectable advanced HCC patients with AFP levels ≥20 ng/mL, it was observed that early responders to lenvatinib based on AFP levels achieved significantly higher ORR and disease control rates compared to non-responders (55). Here, AFP is linked to hepatocellular carcinoma.